<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00925821</url>
  </required_header>
  <id_info>
    <org_study_id>DSMM XII</org_study_id>
    <nct_id>NCT00925821</nct_id>
  </id_info>
  <brief_title>Lenalidomide-Adriamycin-Dexamethasone (RAD) Induction Followed by Stem Cell Transplant in Newly Diagnosed Multiple Myeloma</brief_title>
  <official_title>Lenalidomide (Revlimid®), Adriamycin and Dexamethasone (RAD)as an Induction Therapy in Newly Diagnosed Multiple Myeloma Followed by a Risk-Defined Transplant Strategy and Lenalidomide Maintenance - A Multicenter Phase II Trial by Deutsche Studiengruppe Multiples Myeloma (DSMM XII)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wuerzburg University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ClinAssess GmbH</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Celgene Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>medac GmbH</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Wuerzburg University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Subjects up to the age of 65 years with newly diagnosed multiple myeloma requiring treatment
      are eligible. Minimal pretreatment (2 cycles of chemotherapy; local irradiation; surgery) is
      permitted. After enrollment, patients are to receive four cycles of RAD induction treatment:
      a combination of lenalidomide (Revlimid), adriamycin, and dexamethasone. If at least a
      minimal response is achieved to RAD, they will undergo chemomobilization (cyclophosphamide,
      etoposide) of peripheral blood stem cells and one uniform cycle of high-dose melphalan
      chemotherapy followed by a first stem cell transplant. If any of the high-risk features (such
      as elevated beta 2-microglobulin, adverse cytogenetic factors, elevated LDH, Ig A isotype)
      were present at diagnosis, patients will be allocated to a consolidative allogeneic
      transplant following dose-reduced conditioning. If no appropriate donor is available, the
      patient does not consent or lacks of high-risk features a second autograft following
      high-dose melphalan will be delivered. All patients will proceed to lenalidomide maintenance
      (one year) following hematopoietic reconstitution.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2009</start_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response rate to RAD induction and transplant (stringent CR, CR, very good PR)</measure>
    <time_frame>9 months from start of treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>9 months from start of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence and relationship of severe adverse events</measure>
    <time_frame>1 year from start of treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">146</enrollment>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>Allogeneic stem cell transplant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Second scheduled transplantation performed from an HLA-matched MRD or MUD after conditioning with treosulfan and fludarabine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High-dose melphalan chemotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Second high-dose melphalan therapy followed by transplantation of peripheral blood stem cells</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>allogeneic stem cell transplant versus second autologous transplantation</intervention_name>
    <description>Transplantation of stem cells from a MRD or MUD, respectively after dose-reduced conditioning versus autologous stem cell graft after preparation with melphalan 200 mg/m²</description>
    <arm_group_label>Allogeneic stem cell transplant</arm_group_label>
    <arm_group_label>High-dose melphalan chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RAD</intervention_name>
    <description>After enrollment, patients are to receive four cycles of RAD induction treatment: a combination of lenalidomide (Revlimid), adriamycin, and dexamethasone.</description>
    <arm_group_label>Allogeneic stem cell transplant</arm_group_label>
    <arm_group_label>High-dose melphalan chemotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written informed consent

          -  Newly diagnosed multiple myeloma

          -  Maximum of one prior systemic therapy (2 cycles)

          -  Presence of CRAB criteria

          -  Measurable disease parameters

          -  Left ventricular ejection fraction at least 55%

          -  DLCO of at least 60%

          -  Adequate bone marrow function

          -  Use of adequate contraception for female subjects with childbearing potential and all
             male subjects

          -  Eligible for autologous and allogeneic stem cell transplantation

          -  Bone marrow baseline sample evaluable for interphase cytogenetics

        Exclusion Criteria:

          -  Any serious medical conditions preventing the subject from written informed consent

          -  Progressive disease (PD) to any initial treatment

          -  Pregnant or lactating females

          -  Any condition, including the presence of laboratory abnormalities, which places the
             subject at unacceptable risk if he/she were to participate in the study or confounds
             the ability to interpret data

          -  Use of any other experimental drug or therapy within 28 days of baseline

          -  Preexisting neuropathy of ≥ grade 2 severity

          -  Known hypersensitivity to thalidomide

          -  Any prior use of lenalidomide

          -  Positive for HIV or infectious hepatitis, type A, B or C after serologic testing

          -  Serum creatinine despite induction therapy ≥ 2.0 mg/dL
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ralf C Bargou, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wuerzburg University Hospital, Dept. of Internal Medicine II</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Charité University Hospital - Virchow Klinikum</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dresden University Hospital</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Erlangen University Hospital</name>
      <address>
        <city>Erlangen</city>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Freiburg University Hospital</name>
      <address>
        <city>Freiburg</city>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jena University Hospital</name>
      <address>
        <city>Jena</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kiel University Hospital</name>
      <address>
        <city>Kiel</city>
        <zip>24105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Munich Grosshadern University Hospital</name>
      <address>
        <city>Munich</city>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital of Munich Technical University</name>
      <address>
        <city>Munich</city>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Nuremberg</name>
      <address>
        <city>Nuremberg</city>
        <zip>90419</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regensburg University Hospital</name>
      <address>
        <city>Regensburg</city>
        <zip>93053</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rostock University Hospital</name>
      <address>
        <city>Rostock</city>
        <zip>18057</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ulm University Hospital</name>
      <address>
        <city>Ulm</city>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.lymphome.de/Gruppen/MMSG/index.jsp</url>
    <description>Website of the German Lymphoma Competence Net</description>
  </link>
  <link>
    <url>http://myeloma.org/main.jsp?source=tab&amp;type=tab&amp;tab_id=23</url>
    <description>Site of the International Myeloma Foundation</description>
  </link>
  <verification_date>June 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 16, 2009</study_first_submitted>
  <study_first_submitted_qc>June 19, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 22, 2009</study_first_posted>
  <last_update_submitted>June 27, 2012</last_update_submitted>
  <last_update_submitted_qc>June 27, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 28, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Allogeneic stem cell transplantation</keyword>
  <keyword>Lenalidomide</keyword>
  <keyword>IMiD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Lenalidomide</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Thalidomide</mesh_term>
    <mesh_term>Melphalan</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

